
    
      Single-center, randomized, double-blind, placebo-controlled, single ascending dose, safety
      and tolerability study of TNX-201 capsules in healthy volunteers. Three successive cohorts
      are planned with doses of TNX-201 capsules, 35 mg, 70 mg, and 140 mg, respectively. Each
      cohort will consist of 15 subjects, and subjects will be randomly assigned to TNX-201,
      racemic isometheptene, or placebo capsules.
    
  